UK and US based biotech firm Orchard Therapeutics has secured funding of $150m to expand its work in gene therapy. The company is developing a new treatment for the rare blood disorder called hemophilia B, which affects about one million people worldwide. ’s portfolio of rare disease gene therapies, and builds on previous financing of $140m.
UK and US based biotech firm Orchard Therapeutics has secured funding of $150m to expand its work in gene therapy. The financing followed the company’s acquisition in April of GlaxoSmithKline’s portfolio of rare disease gene therapies, and builds on previous financing of $140m.